US4444784A
(en)
*
|
1980-08-05 |
1984-04-24 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4432996A
(en)
*
|
1980-11-17 |
1984-02-21 |
Merck & Co., Inc. |
Hypocholesterolemic fermentation products and process of preparation
|
JPS57185275A
(en)
*
|
1981-05-07 |
1982-11-15 |
Sankyo Co Ltd |
Tetrahydro-dum-4 and tetrahydro-isodum-4 and their derivatives
|
JPS57185276A
(en)
*
|
1981-05-11 |
1982-11-15 |
Sankyo Co Ltd |
Dihydro-dum-4 and dihydro-isodum-4 and their derivative
|
JPS5815968A
(ja)
*
|
1981-07-21 |
1983-01-29 |
Sankyo Co Ltd |
Ml−236b誘導体およびその製法
|
JPS5835144A
(ja)
*
|
1981-08-27 |
1983-03-01 |
Sankyo Co Ltd |
Mb−530b誘導体およびその製造法
|
JPS5889191A
(ja)
*
|
1981-11-20 |
1983-05-27 |
Sankyo Co Ltd |
3−ヒドロキシ−ml−236b誘導体の製造法
|
PH20405A
(en)
*
|
1983-07-21 |
1987-01-05 |
Fujisawa Pharmaceutical Co |
Anti-tumor agent container fr.900216 substance or its pharmaceutically acceptable salts thereof
|
DE3580863D1
(de)
*
|
1984-06-04 |
1991-01-24 |
Merck & Co Inc |
Herstellungsverfahren von hemmstoffen der hmg-coa-reduktase mit einer 3,5-dihydroxypentanoatteilstruktur.
|
US4611068A
(en)
*
|
1984-11-19 |
1986-09-09 |
Merck Frosst Canada, Inc. |
Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
|
EP0204287A3
(en)
*
|
1985-06-04 |
1987-07-01 |
Merck & Co. Inc. |
Process for the preparation of hmg-coa reductase inhibitors with a 3,5-dihydroxypentanoate subunit
|
US4611081A
(en)
*
|
1985-07-05 |
1986-09-09 |
Merck & Co., Inc. |
Process for the preparation of HMG-CoA reductase inhibitors intermediates
|
USRE33033E
(en)
*
|
1985-07-05 |
1989-08-22 |
Merck & Co., Inc. |
Process for the preparation of HMG-CoA reductase inhibitors intermediates
|
US4668699A
(en)
*
|
1985-08-05 |
1987-05-26 |
Merck & Co., Inc. |
Novel HMG-CoA reductase inhibitors
|
US5272174A
(en)
*
|
1985-09-13 |
1993-12-21 |
Sankyo Company, Limited |
Hydroxy-ML-236B derivatives, their preparation and use
|
ATE69602T1
(de)
*
|
1985-09-13 |
1991-12-15 |
Sankyo Co |
Hydroxy-ml-236b-derivate, deren herstellung und anwendung.
|
JPH0633312B2
(ja)
*
|
1986-05-02 |
1994-05-02 |
大正製薬株式会社 |
14−ハイドロキシエリスロマイシン誘導体およびその製造方法
|
EP0245990A3
(en)
*
|
1986-05-05 |
1989-07-19 |
Merck & Co. Inc. |
Antihypercholesterolemic compounds
|
EP0245004A3
(en)
*
|
1986-05-05 |
1989-07-26 |
Merck & Co. Inc. |
Antihypercholesterolemic compounds
|
US4937264A
(en)
*
|
1986-05-05 |
1990-06-26 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4771071A
(en)
*
|
1986-05-05 |
1988-09-13 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4766145A
(en)
*
|
1986-05-05 |
1988-08-23 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
EP0245003A3
(en)
*
|
1986-05-05 |
1989-07-19 |
Merck & Co. Inc. |
Antihypercholesterolemic compounds
|
US4661483A
(en)
*
|
1986-05-05 |
1987-04-28 |
Merck & Co., Inc. |
Antihypercholesterolemic lactone compounds, compositions and use
|
US4864038A
(en)
*
|
1986-05-05 |
1989-09-05 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4847306A
(en)
*
|
1986-05-05 |
1989-07-11 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
USRE36481E
(en)
*
|
1986-06-23 |
2000-01-04 |
Merck & Co., Inc. |
HMG-CoA reductase inhibitors
|
US5116870A
(en)
*
|
1986-06-23 |
1992-05-26 |
Merck & Co., Inc. |
HMG-CoA reductase inhibitors
|
US4940727A
(en)
*
|
1986-06-23 |
1990-07-10 |
Merck & Co., Inc. |
Novel HMG-CoA reductase inhibitors
|
EP0276807A3
(en)
*
|
1987-01-27 |
1988-10-12 |
Warner-Lambert Company |
Lipid regulating compositions
|
US4833258A
(en)
*
|
1987-02-17 |
1989-05-23 |
Merck & Co., Inc. |
Intermediates useful in the preparation of HMG-COA reductase inhibitors
|
DE3869282D1
(de)
*
|
1987-09-02 |
1992-04-23 |
Merck & Co Inc |
Inhibitoren von hmg-coa-reduktase.
|
US4997848A
(en)
|
1987-10-27 |
1991-03-05 |
Sankyo Company, Limited |
Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
|
US4857547A
(en)
*
|
1988-01-07 |
1989-08-15 |
Merck & Co., Inc. |
Novel HMG-CoA reductase inhibitors
|
US5021453A
(en)
*
|
1988-03-02 |
1991-06-04 |
Merck & Co., Inc. |
3-keto HMG-CoA reductase inhibitors
|
US5047549A
(en)
*
|
1988-03-21 |
1991-09-10 |
E. R. Squibb & Sons, Inc. |
Derivatives of pravastatin for inhibiting cholesterol biosynthesis
|
US5155229A
(en)
*
|
1988-03-21 |
1992-10-13 |
E. R. Squibb & Sons, Inc. |
Derivatives of pravastatin and method of making the same
|
US4857522A
(en)
*
|
1988-03-21 |
1989-08-15 |
E. R. Squibb & Sons, Inc. |
Derivatives of pravastatin for inhibiting cholesterol biosynthesis
|
US5030447A
(en)
*
|
1988-03-31 |
1991-07-09 |
E. R. Squibb & Sons, Inc. |
Pharmaceutical compositions having good stability
|
US5180589A
(en)
*
|
1988-03-31 |
1993-01-19 |
E. R. Squibb & Sons, Inc. |
Pravastatin pharmaceuatical compositions having good stability
|
US4997755A
(en)
*
|
1988-04-15 |
1991-03-05 |
Merck & Co., Inc. |
HMG-CoA reductase inhibitors produced by Nocardia sp. (MA 6455)
|
US4963538A
(en)
*
|
1988-06-29 |
1990-10-16 |
Merck & Co., Inc. |
5-oxygenated HMG-CoA reductase inhibitors
|
US5075327A
(en)
*
|
1988-08-10 |
1991-12-24 |
Hoffmann-La Roche Inc. |
Antipsoriatic agents
|
US5073568A
(en)
*
|
1988-11-14 |
1991-12-17 |
Hoffmann-La Roche Inc. |
Antipsoriatic agents
|
US5021451A
(en)
*
|
1988-11-14 |
1991-06-04 |
Hoffman-La Roche Inc. |
Method for inhibiting hyperproliferative diseases
|
US5200549A
(en)
*
|
1988-11-14 |
1993-04-06 |
Hoffman-La Roche Inc. |
Antipsoriatic agents
|
US5376383A
(en)
*
|
1988-11-21 |
1994-12-27 |
Merck & Co., Inc. |
Method for enhancing the lowering of plasma-cholesterol levels
|
US5260305A
(en)
*
|
1988-12-12 |
1993-11-09 |
E. R. Squibb & Sons, Inc. |
Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
|
JP2763782B2
(ja)
*
|
1989-02-14 |
1998-06-11 |
旭電化工業株式会社 |
メバロン酸の製造方法
|
US5166364A
(en)
*
|
1989-02-27 |
1992-11-24 |
E. R. Squibb & Sons, Inc. |
Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
|
CA2016467A1
(en)
|
1989-06-05 |
1990-12-05 |
Martin Eisman |
Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
|
US5001148A
(en)
*
|
1989-06-07 |
1991-03-19 |
E. R. Squibb & Sons, Inc. |
Mevinic acid derivatives
|
US5041562A
(en)
*
|
1989-06-09 |
1991-08-20 |
Merck & Co., Inc. |
3-keto HMG-CoA reductase inhibitors
|
US5102911A
(en)
*
|
1989-06-09 |
1992-04-07 |
Merck & Co, Inc. |
4-Substituted HMG-CoA reductase inhibitors
|
US4970231A
(en)
*
|
1989-06-09 |
1990-11-13 |
Merck & Co., Inc. |
4-substituted HMG-CoA reductase inhibitors
|
US5001241A
(en)
*
|
1989-06-09 |
1991-03-19 |
Merck & Co., Inc. |
3-KETO HMG-CoA reductase inhibitors
|
US5010105A
(en)
*
|
1989-06-09 |
1991-04-23 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4937259A
(en)
*
|
1989-06-09 |
1990-06-26 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4997849A
(en)
*
|
1989-06-23 |
1991-03-05 |
Merck & Co., Inc. |
Microbial transformation of simvastatin
|
US4965200A
(en)
*
|
1989-06-23 |
1990-10-23 |
Merck & Co., Inc. |
Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
US5316765A
(en)
*
|
1989-09-07 |
1994-05-31 |
Karl Folkers Foundation For Biomedical And Clinical Research |
Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
|
US5212296A
(en)
*
|
1989-09-11 |
1993-05-18 |
E. I. Du Pont De Nemours And Company |
Expression of herbicide metabolizing cytochromes
|
US5173487A
(en)
*
|
1989-11-13 |
1992-12-22 |
E. R. Squibb & Sons, Inc. |
Mevinic acid derivatives
|
US5177104A
(en)
*
|
1990-04-03 |
1993-01-05 |
E. R. Squibb & Sons, Inc. |
6-α-hydroxy derivatives of mevinic acids
|
GB9007738D0
(en)
*
|
1990-04-05 |
1990-06-06 |
British Bio Technology |
Compounds
|
US5089523A
(en)
*
|
1990-05-11 |
1992-02-18 |
E. R. Squibb & Sons, Inc. |
Fluorinated derivatives of mevinic acids
|
US6630502B2
(en)
|
1990-05-15 |
2003-10-07 |
E.R. Squibb & Sons, Inc. |
Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
|
US5140012A
(en)
*
|
1990-05-31 |
1992-08-18 |
E. R. Squibb & Sons, Inc. |
Method for preventing onset of restenosis after angioplasty employing pravastatin
|
US5622985A
(en)
*
|
1990-06-11 |
1997-04-22 |
Bristol-Myers Squibb Company |
Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
|
US5264455A
(en)
*
|
1990-07-06 |
1993-11-23 |
E. R. Squibb & Sons, Inc. |
Sulfur-substituted mevinic acid derivatives
|
US5223415A
(en)
*
|
1990-10-15 |
1993-06-29 |
Merck & Co., Inc. |
Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
|
IE75349B1
(en)
*
|
1991-03-07 |
1997-08-27 |
Lonza Ag |
A process for the terminal hydroxylation of ethyl groups on aromatic 5- or 6-membered heterocyclic compounds
|
US5225202A
(en)
*
|
1991-09-30 |
1993-07-06 |
E. R. Squibb & Sons, Inc. |
Enteric coated pharmaceutical compositions
|
US5286746A
(en)
*
|
1991-12-20 |
1994-02-15 |
E. R. Squibb & Sons, Inc. |
Sulfur-substituted mevinic acid derivatives
|
US5620876A
(en)
*
|
1992-04-29 |
1997-04-15 |
E. R. Squibb & Sons, Inc. |
Enzymatic hydrolysis and esterification processes for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
|
ZA933359B
(en)
|
1992-05-15 |
1993-12-08 |
Sankyo Co |
Octahydronaphthalene oxime derivatives for cholesterol biosynthesis inhibition, their preparation and use
|
US5369123A
(en)
*
|
1992-10-09 |
1994-11-29 |
E. R. Squibb & Sons, Inc. |
Nitrogen-substituted mevinic acid derivatives useful as HMG-CoA reductase inhibitors
|
NZ250609A
(en)
*
|
1992-12-28 |
1995-07-26 |
Sankyo Co |
Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
|
IL108432A
(en)
*
|
1993-01-29 |
1997-09-30 |
Sankyo Co |
DERIVATIVES OF 3, 5-DIHYDROXY-7- £1, 2, 6, 7, 8, 8a-HEXAHYDRO-2- METHYL-8- (SUBSTITUTED ALKANOYLOXY)-1-NAPHTHYL| HEPTANOIC ACID AND THEIR LACTONES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
FR2709126B1
(fr)
*
|
1993-08-18 |
1995-09-29 |
Adir |
Nouveaux dérivés de naphtalène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
|
US6043064A
(en)
*
|
1993-10-22 |
2000-03-28 |
Bristol-Myers Squibb Company |
Enzymatic hydroxylation process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
|
WO1995012661A1
(en)
*
|
1993-11-02 |
1995-05-11 |
Merck & Co., Inc. |
Dna encoding triol polyketide synthase
|
WO1995013063A1
(en)
*
|
1993-11-09 |
1995-05-18 |
Merck & Co., Inc. |
HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
|
US6369103B1
(en)
|
1994-01-18 |
2002-04-09 |
Bristol-Myers Squibb Company |
Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
|
US5681278A
(en)
*
|
1994-06-23 |
1997-10-28 |
Cormedics Corp. |
Coronary vasculature treatment method
|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
US5616595A
(en)
*
|
1995-06-07 |
1997-04-01 |
Abbott Laboratories |
Process for recovering water insoluble compounds from a fermentation broth
|
US5942423A
(en)
*
|
1995-06-07 |
1999-08-24 |
Massachusetts Institute Of Technology |
Conversion of compactin to pravastatin by actinomadura
|
US5900433A
(en)
*
|
1995-06-23 |
1999-05-04 |
Cormedics Corp. |
Vascular treatment method and apparatus
|
NZ286920A
(en)
*
|
1995-07-03 |
1997-06-24 |
Sankyo Co |
Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
|
KR100186758B1
(ko)
*
|
1996-08-09 |
1999-04-01 |
영진약품공업 주식회사 |
프라바스타틴(pravastatin)전구체의제조방법
|
EP0989852A4
(en)
*
|
1997-01-17 |
2002-11-13 |
Bristol Myers Squibb Co |
METHODS FOR TREATING ATHEROSCLEROSE THROUGH AN MPT INHIBITOR AND CHOLESTEROL LEVELS LOWERING MEDICINES
|
US6066653A
(en)
*
|
1997-01-17 |
2000-05-23 |
Bristol-Myers Squibb Co. |
Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
|
KR100210482B1
(ko)
*
|
1997-04-10 |
1999-07-15 |
김종인 |
스트렙토마이세스엑스포리아투스(streptomycesexfoliatus)yj-118과이를이용한프라바스타틴나트륨의제조방법
|
EP0877089A1
(en)
|
1997-05-07 |
1998-11-11 |
Gist-Brocades B.V. |
HMG-CoA reductase inhibitor preparation process
|
US20010006644A1
(en)
|
1997-07-31 |
2001-07-05 |
David J. Bova |
Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
|
AU8460698A
(en)
|
1997-08-07 |
1999-03-01 |
Kyowa Hakko Kogyo Co. Ltd. |
Process for the preparation of hmg-coa reductase inhibitors
|
EP1015600A1
(en)
*
|
1997-08-22 |
2000-07-05 |
Dsm N.V. |
Statin production by fermentation
|
GT199800127A
(es)
|
1997-08-29 |
2000-02-01 |
|
Combinaciones terapeuticas.
|
US6177121B1
(en)
|
1997-09-29 |
2001-01-23 |
Purdue Research Foundation |
Composition and method for producing low cholesterol eggs
|
US6147109A
(en)
*
|
1997-10-14 |
2000-11-14 |
The General Hospital Corporation |
Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
|
US6083497A
(en)
|
1997-11-05 |
2000-07-04 |
Geltex Pharmaceuticals, Inc. |
Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
|
US20080275104A1
(en)
*
|
1997-11-25 |
2008-11-06 |
Musc Foundation For Research Development |
Methods of treating juvenile type 1 diabetes mellitus
|
US20060141036A1
(en)
*
|
1997-12-12 |
2006-06-29 |
Andrx Labs Llc |
HMG-CoA reductase inhibitor extended release formulation
|
US20040029962A1
(en)
*
|
1997-12-12 |
2004-02-12 |
Chih-Ming Chen |
HMG-COA reductase inhibitor extended release formulation
|
US6180597B1
(en)
|
1998-03-19 |
2001-01-30 |
Brigham And Women's Hospital, Inc. |
Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
|
SI9800144A
(sl)
*
|
1998-05-21 |
1999-12-31 |
LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. |
Nov biotehnološki postopek pridobivanja 3-hidroksi-ML-236B derivatov poznanih kot M-4 in M-4'
|
US20030078211A1
(en)
*
|
1998-06-24 |
2003-04-24 |
Merck & Co., Inc. |
Compositions and methods for inhibiting bone resorption
|
EP1088333A4
(en)
|
1998-06-24 |
2005-08-10 |
Merck & Co Inc |
METHOD AND COMPOSITIONS FOR CONNECTING OSTEOPROSIS
|
US6423751B1
(en)
|
1998-07-14 |
2002-07-23 |
The Brigham And Women's Hospital, Inc. |
Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
|
US5985907A
(en)
*
|
1998-08-12 |
1999-11-16 |
Health Research, Inc. |
Method for inhibiting growth of methanogens
|
SI20070A
(sl)
|
1998-09-18 |
2000-04-30 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Nove soli inhibitorjev HMG-CoA reduktaze
|
SI20305A
(sl)
*
|
1999-08-06 |
2001-02-28 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Kristali natrijeve soli pravastatina
|
US20080213378A1
(en)
*
|
1998-10-01 |
2008-09-04 |
Elan Pharma International, Ltd. |
Nanoparticulate statin formulations and novel statin combinations
|
US8293277B2
(en)
*
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
ID29270A
(id)
|
1998-11-20 |
2001-08-16 |
Rtp Pharma Inc |
Partikel-partikel mikro yang distabilkan oleh fosfolipid yang dapat menyebar
|
SI20109A
(sl)
*
|
1998-12-16 |
2000-06-30 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Stabilna farmacevtska formulacija
|
US6391583B1
(en)
|
1998-12-18 |
2002-05-21 |
Wisconsin Alumni Research Foundation |
Method of producing antihypercholesterolemic agents
|
US6562860B1
(en)
*
|
1998-12-23 |
2003-05-13 |
G. D. Searle & Co. |
Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications
|
AU2157400A
(en)
|
1998-12-23 |
2000-07-31 |
G.D. Searle & Co. |
Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
|
CZ20012340A3
(cs)
|
1998-12-23 |
2001-11-14 |
G. D. Searle Llc |
Kombinace inhibitorů transportu kyčelní ľlučové kyseliny a proteinových inhibitorů cholesteryl-esterového přenosu pro kardiovaskulární indikace
|
WO2000038721A1
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
|
EP1140186B1
(en)
|
1998-12-23 |
2003-06-04 |
G.D. Searle LLC. |
Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
|
DE69908644T2
(de)
|
1998-12-23 |
2004-05-13 |
G.D. Searle Llc, Chicago |
Kombnationen von cholesteryl ester transfer protein inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
|
NZ512532A
(en)
*
|
1998-12-23 |
2003-12-19 |
G |
Combinations for treating cardiovascular diseases like hypercholesterolemia and atherosclerosis
|
DE69907960T2
(de)
*
|
1998-12-23 |
2004-02-26 |
G.D. Searle Llc, Chicago |
Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen
|
WO2000043533A1
(fr)
|
1999-01-20 |
2000-07-27 |
Kyowa Hakko Kogyo Co., Ltd. |
Procede de production d'inhibiteurs de la hmg coa-reducatase
|
ATE441702T1
(de)
|
1999-01-29 |
2009-09-15 |
Kyowa Hakko Bio Co Ltd |
Verfahren zur herstellung eines hmg-coa reduktase hemmers
|
US6682913B1
(en)
|
1999-02-03 |
2004-01-27 |
Institute For Drug Research Ltd. |
Microbial process for preparing pravastatin
|
US6569461B1
(en)
|
1999-03-08 |
2003-05-27 |
Merck & Co., Inc. |
Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
|
HUP9902352A1
(hu)
*
|
1999-07-12 |
2000-09-28 |
Gyógyszerkutató Intézet Kft. |
Eljárás pravasztatin mikrobiológiai előállítására
|
SE9903028D0
(sv)
*
|
1999-08-27 |
1999-08-27 |
Astra Ab |
New use
|
UA77151C2
(en)
*
|
1999-08-30 |
2006-11-15 |
Sanofi Aventis Deutschland |
Use of ramipril for prevention of cardiovascular events
|
EP1265604B1
(en)
|
1999-11-30 |
2006-10-18 |
TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság |
Process for recovering statin compounds from a fermentation broth
|
AU779306B2
(en)
*
|
1999-12-14 |
2005-01-13 |
Teva Gyogyszergyar Reszvenytarsasag |
Novel forms of pravastatin sodium
|
IN191580B
(da)
*
|
1999-12-17 |
2003-12-06 |
Ranbaxy Lab Ltd |
|
WO2001054728A1
(en)
*
|
2000-01-28 |
2001-08-02 |
Asahi Kasei Kabushiki Kaisha |
NOVEL REMEDIES WITH THE USE OF β3 AGONIST
|
ES2328446T5
(es)
|
2000-02-04 |
2014-02-27 |
Children's Hospital Research Foundation |
Uso de lipasa ácida lisosomal para tratar la aterosclerosis y enfermedades asociadas
|
US6586434B2
(en)
|
2000-03-10 |
2003-07-01 |
G.D. Searle, Llc |
Method for the preparation of tetrahydrobenzothiepines
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
WO2001068096A2
(en)
*
|
2000-03-10 |
2001-09-20 |
Pharmacia Corporation |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
US6558659B2
(en)
|
2000-04-10 |
2003-05-06 |
Teva Pharmaceutical Industries Ltd. |
Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
|
JP2003530437A
(ja)
*
|
2000-04-13 |
2003-10-14 |
マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ |
Aβ42低下物質
|
DE10030375A1
(de)
*
|
2000-06-21 |
2002-01-03 |
Bayer Ag |
Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
|
AU2001284413A1
(en)
*
|
2000-08-30 |
2002-03-13 |
Sankyo Company Limited |
Medicinal compositions for preventing or treating heart failure
|
JO2654B1
(en)
|
2000-09-04 |
2012-06-17 |
شركة جانسين فارماسوتيكا ان. في |
Multiple aryl caroxa amides are useful as lipid - lowering agents
|
US8586094B2
(en)
|
2000-09-20 |
2013-11-19 |
Jagotec Ag |
Coated tablets
|
MXPA03002963A
(es)
*
|
2000-10-05 |
2005-01-25 |
Biogal Gyogyszergyar |
Pravastatina de sodio sustancialmente libre de pravastatina lactona y epi-pravastatina, y composiciones que la contienen.
|
US6936731B2
(en)
*
|
2000-10-05 |
2005-08-30 |
TEVA Gyógyszergyár Részvénytársaság |
Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
|
US20050215636A1
(en)
*
|
2000-10-05 |
2005-09-29 |
Vilmos Keri |
Pravastatin sodium substantially free of pravastatin lactone and EPI-pravastatin, and compositions containing same
|
US6534540B2
(en)
|
2000-10-06 |
2003-03-18 |
George Kindness |
Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
|
US20030162829A1
(en)
*
|
2000-10-06 |
2003-08-28 |
George Kindness |
Combination of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
|
JP3236282B1
(ja)
*
|
2000-10-16 |
2001-12-10 |
三共株式会社 |
プラバスタチンを精製する方法
|
JP2002121172A
(ja)
*
|
2000-10-16 |
2002-04-23 |
Sankyo Co Ltd |
プラバスタチン又はその薬理上許容される塩の精製方法
|
US6916849B2
(en)
|
2000-10-23 |
2005-07-12 |
Sankyo Company, Limited |
Compositions for improving lipid content in the blood
|
CA2428204A1
(en)
|
2000-11-07 |
2002-05-16 |
Sankyo Company, Limited |
Lipid peroxide-lowering compositions
|
US6777552B2
(en)
*
|
2001-08-16 |
2004-08-17 |
Teva Pharmaceutical Industries, Ltd. |
Processes for preparing calcium salt forms of statins
|
JO2409B1
(en)
*
|
2000-11-21 |
2007-06-17 |
شركة جانسين فارماسوتيكا ان. في |
Second-phenyl carboxy amides are useful as lipid-lowering agents
|
US20030232834A1
(en)
*
|
2001-03-08 |
2003-12-18 |
Keller Bradley T |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
RU2003131338A
(ru)
*
|
2001-03-27 |
2005-02-10 |
Рэнбакси Лабораториз Лимитед (In) |
Стабильная фармацевтическая композиция на основе правастатина
|
JO2390B1
(en)
*
|
2001-04-06 |
2007-06-17 |
شركة جانسين فارماسوتيكا ان. في |
Diphenylcarboxamides act as lipid-lowering agents
|
DK1385856T3
(da)
|
2001-04-11 |
2006-05-15 |
Bristol Myers Squibb Co |
Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
|
MXPA03009562A
(es)
|
2001-04-18 |
2004-02-12 |
Genzyme Corp |
METODO PARA TRATAR EL SiNDROME X CON POLIAMINAS ALIFATICAS.
|
US6699886B2
(en)
*
|
2001-05-31 |
2004-03-02 |
Cellegy Pharmaceuticals, Inc. |
Store operated calcium influx inhibitors and methods of use
|
JP2004536826A
(ja)
*
|
2001-06-21 |
2004-12-09 |
アンドルックス ファーマスーティカルズ インコーポレーテッド |
プラバスタチンを含む安定な薬剤組成物
|
US20040180087A1
(en)
*
|
2001-06-21 |
2004-09-16 |
Boyong Li |
Stable controlled release pharmaceutical compositions containing pravastatin
|
US20040092565A1
(en)
*
|
2001-07-25 |
2004-05-13 |
George Kindness |
Composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin
|
US20040077625A1
(en)
*
|
2001-07-25 |
2004-04-22 |
Tremont Samuel J. |
Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
|
AU2001295867A1
(en)
*
|
2001-09-27 |
2003-04-07 |
Biocon Limited |
Process for producing pravastatin sodium salt using streptomyces flavidovirens dsm 14455
|
KR100414334B1
(ko)
*
|
2001-09-29 |
2004-01-07 |
코바이오텍 (주) |
프라바스타틴 나트륨의 생산 방법
|
EP1572892A4
(en)
*
|
2001-10-18 |
2007-08-22 |
Bristol Myers Squibb Co |
HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
|
US7238671B2
(en)
*
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
MXPA04003524A
(es)
*
|
2001-11-02 |
2004-07-23 |
Searle Llc |
Compuestos de benzotiepina monofluorados y difluorados novedosos como inhibidores de transporte de acido biliar co-dependiente de sodio apical (asbt) y captacion de taurocolato.
|
US6806381B2
(en)
*
|
2001-11-02 |
2004-10-19 |
Bristol-Myers Squibb Company |
Process for the preparation of aniline-derived thyroid receptor ligands
|
AU2002348276A1
(en)
*
|
2001-11-16 |
2003-06-10 |
Bristol-Myers Squibb Company |
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
|
US6831102B2
(en)
*
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
EP1465869B1
(en)
|
2001-12-21 |
2013-05-15 |
Exelixis Patent Company LLC |
Modulators of lxr
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
ATE521599T1
(de)
*
|
2001-12-21 |
2011-09-15 |
X Ceptor Therapeutics Inc |
Heterocyclische modulatoren von nukleären rezeptoren
|
WO2003061604A2
(en)
|
2002-01-17 |
2003-07-31 |
Pharmacia Corporation |
Novel alkyl/aryl hydroxy or keto thiepines.
|
KR100379075B1
(en)
*
|
2002-03-07 |
2003-04-08 |
Jinis Biopharmaceuticals Co |
Method for producing low cholesterol animal food product and food product therefrom
|
KR100828653B1
(ko)
*
|
2002-03-18 |
2008-05-09 |
바이오콘 리미티드 |
목적하는 입자 크기를 갖는 비 결정성 Hmg-CoA리덕타제 억제제
|
EA200401227A1
(ru)
*
|
2002-03-22 |
2005-04-28 |
Рэнбакси Лабораториз Лимитед |
Система доставки лекарства с контролируемым высвобождением, включающая правастатин
|
CA2480325A1
(en)
*
|
2002-04-16 |
2003-10-30 |
Merck & Co., Inc. |
Solid forms of salts with tyrosine kinase activity
|
WO2003094845A2
(en)
|
2002-05-08 |
2003-11-20 |
Bristol-Myers Squibb Company |
Pyridine-based thyroid receptor ligands
|
CN102533972B
(zh)
|
2002-05-09 |
2014-07-02 |
布赖汉姆妇女医院 |
作为心血管病的标志和治疗靶的1l1rl-1
|
JP4478563B2
(ja)
*
|
2002-05-14 |
2010-06-09 |
プレゼント インヴェストメンツ エルエルシー |
送信信号の形成方法
|
US7057046B2
(en)
*
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
AU2003241477A1
(en)
*
|
2002-06-10 |
2003-12-22 |
Elan Pharma International, Ltd. |
Nanoparticulate polycosanol formulations and novel polycosanol combinations
|
US20050182106A1
(en)
*
|
2002-07-11 |
2005-08-18 |
Sankyo Company, Limited |
Medicinal composition for mitigating blood lipid or lowering blood homocysteine
|
EP1526857A1
(de)
*
|
2002-07-23 |
2005-05-04 |
Nutrinova Nutrition Specialties & Food Ingredients GmbH |
Cholesterinsenkendes mittel aus ballaststoffen und cholesterinsenkenden stoffen
|
US20050182036A1
(en)
*
|
2002-08-02 |
2005-08-18 |
Sankyo Company, Limited |
Medicinal composition containing an HMG-CoA reductase inhibitor
|
US20050187204A1
(en)
*
|
2002-08-08 |
2005-08-25 |
Sankyo Company, Limited |
Medicinal composition for lowering blood lipid level
|
UA79300C2
(en)
*
|
2002-08-12 |
2007-06-11 |
Janssen Pharmaceutica Nv |
N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
|
AU2003278744B2
(en)
|
2002-08-28 |
2010-07-29 |
Harbor Biosciences, Inc. |
Therapeutic treatment methods
|
US20080293750A1
(en)
*
|
2002-10-17 |
2008-11-27 |
Anna Helgadottir |
Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
|
US20060019269A1
(en)
*
|
2002-10-17 |
2006-01-26 |
Decode Genetics, Inc. |
Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
|
WO2004037181A2
(en)
*
|
2002-10-23 |
2004-05-06 |
Bristol-Myers Squibb Company |
Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
|
US20080145424A1
(en)
*
|
2002-10-24 |
2008-06-19 |
Enos Phramaceuticals, Inc. |
Sustained release L-arginine formulations and methods of manufacture and use
|
EP1562555A2
(en)
*
|
2002-10-24 |
2005-08-17 |
Enos Pharmaceuticals, Inc. |
Sustained release l-arginine formulations and methods of manufacture and use
|
US7098235B2
(en)
*
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
US20040110241A1
(en)
*
|
2002-12-06 |
2004-06-10 |
Segal Mark S. |
Materials and methods for monitoring vascular endothelial function
|
US20040198800A1
(en)
*
|
2002-12-19 |
2004-10-07 |
Geoffrey Allan |
Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
|
US20040132771A1
(en)
*
|
2002-12-20 |
2004-07-08 |
Pfizer Inc |
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
|
DE60323536D1
(de)
|
2002-12-20 |
2008-10-23 |
Pfizer Prod Inc |
Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
|
CA2510320C
(en)
*
|
2002-12-20 |
2012-10-09 |
St. James Associates Llc/Faber Research Series |
Coated particles for sustained-release pharmaceutical administration
|
DE10261067A1
(de)
*
|
2002-12-24 |
2004-08-05 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
|
DE10261061A1
(de)
*
|
2002-12-24 |
2004-07-15 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Diätetisches Lebensmittel zur positiven Beeinflussung der kardiovaskulären Gesundheit
|
EP1587783A4
(en)
*
|
2003-01-24 |
2006-11-08 |
Bristol Myers Squibb Co |
CYCLOALKYL-CONTAINING ANILID LIGANDS FOR THE THYROID RECEPTOR
|
TW200504021A
(en)
*
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
WO2004071431A2
(en)
*
|
2003-02-05 |
2004-08-26 |
Myriad Genetics, Inc. |
Method and composition for treating neurodegenerative disorders
|
EP1452602A1
(en)
*
|
2003-02-25 |
2004-09-01 |
Antibiotic Co., |
Method for production of pravastatin by fermentation
|
US7557143B2
(en)
*
|
2003-04-18 |
2009-07-07 |
Bristol-Myers Squibb Company |
Thyroid receptor ligands
|
AU2004233691B2
(en)
*
|
2003-04-28 |
2007-09-20 |
Sankyo Company, Limited |
Sugar intake-ability enhancer
|
ES2421520T3
(es)
|
2003-04-28 |
2013-09-03 |
Daiichi Sankyo Co Ltd |
Potenciador de la producción de adiponectina
|
AR041089A1
(es)
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
|
US7459474B2
(en)
*
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
KR100470078B1
(ko)
*
|
2003-06-12 |
2005-02-04 |
씨제이 주식회사 |
컴팩틴을 프라바스타틴으로 전환할 수 있는 스트렙토마이세스 종(Streptomyces sp.)CJPV 975652 및 그를 이용한 프라바스타틴의 제조방법
|
PL1638937T3
(pl)
*
|
2003-06-18 |
2009-06-30 |
Teva Pharmaceutical Industries Ltd |
Krystaliczna postać XIV soli sodowej fluwastatyny, sposoby jej wytwarzania, kompozycje farmaceutyczne zawierające tę postać oraz sposoby ich stosowania
|
US7368468B2
(en)
*
|
2003-06-18 |
2008-05-06 |
Teva Pharmaceutical Industries Ltd. |
Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
|
US20050043272A1
(en)
*
|
2003-07-11 |
2005-02-24 |
Pro-Pharmaceuticals, Inc. |
Compositions and methods for hydrophobic drug delivery
|
US20050042284A1
(en)
*
|
2003-07-11 |
2005-02-24 |
Myriad Genetics, Incorporated |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
|
US20050037063A1
(en)
*
|
2003-07-21 |
2005-02-17 |
Bolton Anthony E. |
Combined therapies
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
AU2004266740B2
(en)
|
2003-08-21 |
2010-08-26 |
Merck Frosst Canada Ltd |
Cathepsin cysteine protease inhibitors
|
EP1510208A1
(en)
*
|
2003-08-22 |
2005-03-02 |
Fournier Laboratories Ireland Limited |
Pharmaceutical composition comprising a combination of metformin and statin
|
CA2657076A1
(en)
*
|
2003-08-28 |
2005-03-17 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of rosuvastatin calcium
|
NZ544803A
(en)
|
2003-08-29 |
2009-11-27 |
Kowa Co |
Method of stabilizing lipid-rich plaque and method of preventing rupture thereof
|
US20050053664A1
(en)
*
|
2003-09-08 |
2005-03-10 |
Eliezer Zomer |
Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
|
US20050171207A1
(en)
*
|
2003-09-26 |
2005-08-04 |
Myriad Genetics, Incorporated |
Method and composition for combination treatment of neurodegenerative disorders
|
EP1675619A4
(en)
*
|
2003-09-29 |
2010-10-06 |
Palmetto Pharmaceuticals Llc |
EXTENDED RELEASE ARGININE FORMULATIONS, METHODS OF MAKING, AND USES
|
US8227434B1
(en)
|
2003-11-04 |
2012-07-24 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
Materials and methods for treating oncological disorders
|
CA2543596A1
(en)
*
|
2003-11-07 |
2005-05-26 |
Jj Pharma, Inc. |
Hdl-boosting combination therapy complexes
|
PL1689757T3
(pl)
*
|
2003-11-12 |
2015-05-29 |
Sino Med Int Alliance Inc |
Heterocykliczne związki kwasu boronowego
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
CA2546079A1
(en)
*
|
2003-11-17 |
2005-05-26 |
Toyo Shinyaku Co., Ltd. |
Lipometabolism improver containing pine bark extract
|
RU2422450C2
(ru)
|
2003-11-19 |
2011-06-27 |
Метабазис Терапеутикс, Инк. |
Новые фосфорсодержащие тиромиметики
|
PL1641447T3
(pl)
*
|
2003-11-24 |
2009-04-30 |
Teva Gyogyszergyar Zartkoerueen Muekoedoe Reszvenytarsasag |
Sposób oczyszczania prawastatyny
|
WO2005051921A1
(en)
*
|
2003-11-24 |
2005-06-09 |
Teva Pharmaceutical Industries Ltd. |
Crystalline ammonium salts of rosuvastatin
|
JP2007512347A
(ja)
*
|
2003-11-26 |
2007-05-17 |
デューク・ユニバーシティー |
緑内障を予防するかまたは治療する方法
|
CN1277826C
(zh)
*
|
2003-12-01 |
2006-10-04 |
叶红平 |
辉伐他汀及其合成方法和以辉伐他汀为原料药的制剂
|
WO2005056534A1
(en)
*
|
2003-12-02 |
2005-06-23 |
Teva Pharmaceutical Industries Ltd. |
Reference standard for characterization of rosuvastatin
|
KR20060118557A
(ko)
*
|
2003-12-17 |
2006-11-23 |
다이닛본 스미토모 세이야꾸 가부시끼가이샤 |
의약 조성물 및 조합물
|
CN100471835C
(zh)
|
2003-12-23 |
2009-03-25 |
默克公司 |
抗高胆固醇血症化合物
|
US7851624B2
(en)
*
|
2003-12-24 |
2010-12-14 |
Teva Pharamaceutical Industries Ltd. |
Triol form of rosuvastatin and synthesis of rosuvastatin
|
US20070179166A1
(en)
*
|
2003-12-24 |
2007-08-02 |
Valerie Niddam-Hildesheim |
Process for preparation of statins with high syn to anti ratio
|
CA2645396A1
(en)
*
|
2003-12-24 |
2005-07-14 |
Teva Pharmaceutical Industries, Ltd |
Process for preparation of statins with high syn to anti ratio
|
US20070161700A1
(en)
*
|
2004-12-28 |
2007-07-12 |
Kowa Company, Ltd. |
Inhibitor for the formation of y-secretase complex
|
US8163797B2
(en)
*
|
2003-12-31 |
2012-04-24 |
Actavis Elizabeth Llc |
Method of treating with stable pravastatin formulation
|
TWI252253B
(en)
*
|
2004-01-09 |
2006-04-01 |
Chinese Petroleum Corp |
A novel Pseudonocardia sp RMRC PAH4 and a process for bioconverting compactin into pravastatin using the same
|
US8158362B2
(en)
*
|
2005-03-30 |
2012-04-17 |
Decode Genetics Ehf. |
Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
|
US20100216863A1
(en)
*
|
2004-01-30 |
2010-08-26 |
Decode Genetics Ehf. |
Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
|
EP1563837A1
(en)
*
|
2004-02-03 |
2005-08-17 |
Ferrer Internacional, S.A. |
Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
|
EP1718146A2
(en)
*
|
2004-02-13 |
2006-11-08 |
Pro-Pharmaceuticals, Inc. |
Compositions and methods used to treat acne and candida
|
EP1719525B1
(en)
*
|
2004-02-25 |
2014-12-10 |
Kowa Company, Ltd. |
Nuclear transfer promoter for cdc42 protein and method of screening the same
|
JP4711952B2
(ja)
*
|
2004-02-25 |
2011-06-29 |
興和株式会社 |
Racタンパク質の核内移行促進剤及びそのスクリーニング方法
|
SI1725234T2
(sl)
*
|
2004-03-05 |
2016-05-31 |
The Trustees Of The University Of Pennsylvania |
Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih učinkov
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
EP1734819A1
(en)
*
|
2004-03-19 |
2006-12-27 |
Pro-Pharmaceuticals, Inc. |
Compositions and methods for targeting metastatic tumors using multivalent ligand-linked carbohydrate polymers
|
DE602004017784D1
(de)
*
|
2004-03-30 |
2008-12-24 |
Lupin Ltd |
Verbessertes verfahren zur herstellung von 4-hydroxypyran-2-onderivaten
|
US20070166360A1
(en)
*
|
2004-03-31 |
2007-07-19 |
Kowa Co., Ltd. |
External preparation
|
KR100598326B1
(ko)
|
2004-04-10 |
2006-07-10 |
한미약품 주식회사 |
HMG-CoA 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
|
US20070293538A1
(en)
*
|
2004-04-13 |
2007-12-20 |
Myriad Genetics, Incorporated |
Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
|
CA2568542A1
(en)
*
|
2004-05-27 |
2005-12-08 |
Dexcel Pharma Technologies Ltd. |
Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
|
US7803838B2
(en)
*
|
2004-06-04 |
2010-09-28 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
TW200611704A
(en)
*
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
US7145040B2
(en)
*
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
EP1778220A1
(en)
*
|
2004-07-12 |
2007-05-02 |
Phenomix Corporation |
Constrained cyano compounds
|
EP1673351A1
(en)
*
|
2004-07-13 |
2006-06-28 |
Teva Pharmaceutical Industries Ltd. |
A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
US20110217412A1
(en)
*
|
2004-07-30 |
2011-09-08 |
Jinis Biopharmaceuticals Co. |
Cholesterol lowering supplement and low cholesterol egg produced by using the same
|
KR100637762B1
(ko)
*
|
2004-07-30 |
2006-10-23 |
주식회사 지니스 |
저콜레스테롤 란을 생산하기 위한 가금류용 사료첨가제 및 이를 이용한 저콜레스테롤 란의 생산방법
|
WO2006017417A2
(en)
*
|
2004-08-02 |
2006-02-16 |
Pro-Pharmaceuticals, Inc. |
Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
|
AU2005271407A1
(en)
*
|
2004-08-06 |
2006-02-16 |
Transform Pharmaceuticals, Inc. |
Novel fenofibrate formulations and related methods of treatment
|
US20090042979A1
(en)
*
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
EP1786414A4
(en)
*
|
2004-08-06 |
2008-04-09 |
Transform Pharmaceuticals Inc |
NEW PHARMACEUTICAL STATIN COMPOSITIONS AND RELEVANT TREATMENT PROCEDURES
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020853A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
US20070244107A1
(en)
*
|
2004-08-25 |
2007-10-18 |
Waters M Gerard |
Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
|
US20060058261A1
(en)
*
|
2004-09-15 |
2006-03-16 |
Andre Aube |
Chitin derivatives for hyperlipidemia
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
EP2927693A1
(en)
|
2004-10-06 |
2015-10-07 |
The Brigham and Women's Hospital |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
US7517991B2
(en)
*
|
2004-10-12 |
2009-04-14 |
Bristol-Myers Squibb Company |
N-sulfonylpiperidine cannabinoid receptor 1 antagonists
|
MX2007005129A
(es)
*
|
2004-10-27 |
2007-09-11 |
Daiichi Sankyo Co Ltd |
Compuesto de benceno que tiene 2 o mas sustituyentes.
|
US20090196889A1
(en)
*
|
2004-11-22 |
2009-08-06 |
Dexcel Pharma Technologies Ltd. |
Controlled absorption of statins in the intestine
|
TWI307360B
(en)
|
2004-12-03 |
2009-03-11 |
Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag |
Process for constructing strain having compactin hydroxylation ability
|
CN101087606B
(zh)
|
2004-12-09 |
2010-12-29 |
默沙东公司 |
雌激素受体调节剂
|
TW200619204A
(en)
*
|
2004-12-10 |
2006-06-16 |
Kowa Co |
Method for reduction, stabilization and prevention of rupture of lipid rich plaque
|
RU2410118C2
(ru)
*
|
2004-12-15 |
2011-01-27 |
Зольвай Фармасьютиклз Гмбх |
ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ НЭП (НЕЙТРАЛЬНОЙ ЭНДОПЕПТИДАЗЫ), ИНГИБИТОРЫ ЭНДОГЕННОЙ ПРОДУЦИРУЮЩЕЙ ЭНДОТЕЛИН СИСТЕМЫ И ИНГИБИТОРЫ ГМГ (ГИДРОКСИМЕТИЛГЛУТАРИЛ)СоА РЕДУКТАЗЫ
|
US7589088B2
(en)
*
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7635699B2
(en)
*
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US20080194548A1
(en)
*
|
2005-01-06 |
2008-08-14 |
Forrest Michael J |
Drug Combination Therapy and Pharmaceutical Compositions for Treating Inflammatory Disorders
|
US7220859B2
(en)
|
2005-01-12 |
2007-05-22 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
WO2006076597A1
(en)
*
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7314882B2
(en)
*
|
2005-01-12 |
2008-01-01 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US20060160850A1
(en)
*
|
2005-01-18 |
2006-07-20 |
Chongqing Sun |
Bicyclic heterocycles as cannabinoid receptor modulators
|
AP2764A
(en)
*
|
2005-01-31 |
2013-09-30 |
Mylan Lab Inc |
Hydroxylated nebivolol metabolites
|
CA2595635A1
(en)
*
|
2005-02-09 |
2006-08-17 |
Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag |
Methods of making pravastatin sodium
|
US7238702B2
(en)
*
|
2005-02-10 |
2007-07-03 |
Bristol-Myers Squibb Company |
Dihydroquinazolinones as 5HT modulators
|
US20070037979A1
(en)
*
|
2005-02-22 |
2007-02-15 |
Valerie Niddam-Hildesheim |
Preparation of rosuvastatin
|
CA2594017C
(en)
*
|
2005-02-22 |
2010-04-20 |
Teva Pharmaceutical Industries Ltd. |
Preparation of rosuvastatin
|
US20070167625A1
(en)
*
|
2005-02-22 |
2007-07-19 |
Anna Balanov |
Preparation of rosuvastatin
|
US20070293535A1
(en)
*
|
2005-02-24 |
2007-12-20 |
Kowa Company, Ltd. |
Nuclear Transfer Promoter for Ddc42 Protein and Method of Screening the Dame
|
WO2007046842A2
(en)
|
2005-03-02 |
2007-04-26 |
Merck & Co., Inc. |
Composition for inhibition of cathepsin k
|
WO2006103661A2
(en)
*
|
2005-03-28 |
2006-10-05 |
Dexcel Pharma Technologies Ltd. |
Controlled absorption of statins in the intestine
|
US20060235028A1
(en)
|
2005-04-14 |
2006-10-19 |
Li James J |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
EP1888050B1
(en)
|
2005-05-17 |
2012-03-21 |
Merck Sharp & Dohme Ltd. |
cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
EP1896074A4
(en)
*
|
2005-05-25 |
2009-04-22 |
Liponex Inc |
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF CORONARY ARTERY DISEASE
|
TW200716679A
(en)
*
|
2005-05-26 |
2007-05-01 |
Bristol Myers Squibb Co |
N-terminally modified GLP-1 receptor modulators
|
EP2174658A1
(en)
|
2005-05-31 |
2010-04-14 |
Mylan Laboratories, Inc |
Compositions comprising nebivolol
|
US7629342B2
(en)
*
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
US7317012B2
(en)
*
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
US20060287342A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Mikkilineni Amarendra B |
Triazolopyrimidine heterocycles as cannabinoid receptor modulators
|
US7632837B2
(en)
*
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
US7452892B2
(en)
*
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
TW200726765A
(en)
*
|
2005-06-17 |
2007-07-16 |
Bristol Myers Squibb Co |
Triazolopyridine cannabinoid receptor 1 antagonists
|
JP5237799B2
(ja)
|
2005-06-27 |
2013-07-17 |
エグゼリクシス パテント カンパニー エルエルシー |
ピラゾールベースのlxrモジュレーター
|
US20070015832A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myriad Genetics, Incorporated |
Methods of treating overactive bladder and urinary incontinence
|
CN101268075A
(zh)
*
|
2005-07-28 |
2008-09-17 |
百时美施贵宝公司 |
作为5-羟色胺受体激动剂和拮抗剂的取代的四氢-1h吡啶并[4,3,b]吲哚
|
KR20080033410A
(ko)
*
|
2005-08-04 |
2008-04-16 |
트렌스폼 파마수티컬스 인코퍼레이티드 |
페노피브레이트 및 스타틴을 포함하는 신규한 제제 및 관련치료방법
|
WO2007022488A2
(en)
*
|
2005-08-16 |
2007-02-22 |
Teva Pharmaceutical Industries Ltd. |
Crystalline rosuvastatin intermediate
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
PE20070335A1
(es)
*
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Benzimidazoles sustituidos y metodos para su preparacion
|
EP1919393A2
(en)
*
|
2005-09-01 |
2008-05-14 |
Prescient Medical, Inc. |
Drugs coated on a device to treat vulnerable plaque
|
US20090297496A1
(en)
*
|
2005-09-08 |
2009-12-03 |
Childrens Hospital Medical Center |
Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
|
WO2007035395A2
(en)
*
|
2005-09-16 |
2007-03-29 |
Virginia Commonwealth University Intellectual Property Foundation |
Therapeutic compositions comprising chorionic gonadotropins and hmg coa reductase inhibitors
|
US8119358B2
(en)
*
|
2005-10-11 |
2012-02-21 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
DE102005049293A1
(de)
*
|
2005-10-15 |
2007-04-26 |
Bayer Healthcare Ag |
Kombinationspräparate von Salzen oder o-Acetylsalicylsäure
|
US20070093468A1
(en)
*
|
2005-10-18 |
2007-04-26 |
Wisler Gerald L |
Methods for treating disorders associated with hyperlipidemia in a mammal
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
AR056155A1
(es)
|
2005-10-26 |
2007-09-19 |
Bristol Myers Squibb Co |
Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
|
WO2007053819A2
(en)
|
2005-10-31 |
2007-05-10 |
Bristol-Myers Squibb Company |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
|
WO2007059372A2
(en)
*
|
2005-11-09 |
2007-05-24 |
St. Jude Children's Research Hospital |
Use of chloroquine to treat metabolic syndrome
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
EP1956090A4
(en)
*
|
2005-11-29 |
2009-04-08 |
Kyowa Hakko Kogyo Kk |
NOVEL PROTEIN AND DNA ENCODING THE PROTEIN
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
WO2007073935A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Lek Pharmaceuticals D.D. |
Heterocyclic compounds
|
EP1976873A2
(en)
*
|
2006-01-11 |
2008-10-08 |
Brystol-Myers Squibb Company |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US7553836B2
(en)
*
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
US20090069275A1
(en)
*
|
2006-02-17 |
2009-03-12 |
Rocca Jose G |
Low flush niacin formulation
|
CA2569776A1
(en)
*
|
2006-02-17 |
2007-08-17 |
Kos Life Sciences, Inc. |
Low flush niacin formulation
|
US20070238770A1
(en)
*
|
2006-04-05 |
2007-10-11 |
Bristol-Myers Squibb Company |
Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
|
EP2010528B1
(en)
|
2006-04-19 |
2017-10-04 |
Novartis AG |
6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
|
EP2574624A1
(en)
|
2006-04-20 |
2013-04-03 |
Amgen Inc. |
GLP-1 compounds
|
EP2012828A2
(en)
*
|
2006-04-28 |
2009-01-14 |
Resolvyx Pharmaceuticals, Inc. |
Compositions and methods for the treatment of cardiovascular disease
|
US20070269503A1
(en)
*
|
2006-05-16 |
2007-11-22 |
James Walter Burgess |
Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
|
US20100022457A1
(en)
*
|
2006-05-26 |
2010-01-28 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
CA2659082A1
(en)
|
2006-06-07 |
2007-12-21 |
Tethys Bioscience, Inc. |
Markers associated with arteriovascular events and methods of use thereof
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US20080044326A1
(en)
*
|
2006-07-04 |
2008-02-21 |
Esencia Co., Ltd. |
Sterilizer for baby products
|
RS53084B
(en)
|
2006-07-05 |
2014-06-30 |
Takeda Gmbh |
COMBINATION OF HMG-COA ROSUVASTATIN REDUCTASE INHIBITOR WITH PHOSPHODIESTERASE 4 INHIBITOR, WHICH IS ROFLUMILAST, ROFLUMILAST-N-OXIDE FOR THE TREATMENT OF INFLAMMATORY LUNG DISEASES
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
US20080033045A1
(en)
*
|
2006-07-07 |
2008-02-07 |
Myriad Genetics, Incorporated |
Treatment of psychiatric disorders
|
US7727978B2
(en)
|
2006-08-24 |
2010-06-01 |
Bristol-Myers Squibb Company |
Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
JP4881385B2
(ja)
|
2006-08-30 |
2012-02-22 |
国立大学法人九州大学 |
スタチン封入ナノ粒子含有医薬組成物
|
EP2698157B1
(en)
|
2006-09-22 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
EP2079448A2
(en)
*
|
2006-10-10 |
2009-07-22 |
Dexcel Pharma Technologies Ltd. |
Improved release of statins in the intestine
|
US20080118572A1
(en)
*
|
2006-10-10 |
2008-05-22 |
Harold Richard Hellstrom |
Methods and compositions for reducing the risk of adverse cardiovascular events associated with the administration of artificial blood
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
EP2089355A2
(en)
|
2006-11-01 |
2009-08-19 |
Brystol-Myers Squibb Company |
Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof
|
US20080161279A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Wisler Gerald L |
Methods of Treating Obesity
|
KR101591656B1
(ko)
|
2007-01-10 |
2016-02-19 |
엠에스디 이탈리아 에스.알.엘. |
폴리(adp-리보오스) 폴리머라아제(parp) 억제제로서의 아미드 치환된 인다졸
|
CA2679403A1
(en)
*
|
2007-03-01 |
2008-09-04 |
Concourse Health Sciences Llc |
Isomers of inositol niacinate and uses thereof
|
US8822497B2
(en)
|
2007-03-01 |
2014-09-02 |
Novartis Ag |
PIM kinase inhibitors and methods of their use
|
CL2008000684A1
(es)
|
2007-03-09 |
2008-08-01 |
Indigene Pharmaceuticals Inc |
Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
|
US20080227846A1
(en)
*
|
2007-03-13 |
2008-09-18 |
Musc Foundation For Research Development |
Methods of treating juvenile type 1 diabetes mellitus
|
TW200904405A
(en)
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Pharmaceutical formulations containing an SGLT2 inhibitor
|
TWI407955B
(zh)
|
2007-03-29 |
2013-09-11 |
Kowa Co |
高脂血症之預防及/或治療劑
|
WO2008124121A1
(en)
*
|
2007-04-06 |
2008-10-16 |
Scidose, Llc |
Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
|
MX2009010925A
(es)
*
|
2007-04-09 |
2009-11-02 |
Scidose Llc |
Combinaciones de estatinas y agente anti-obesidad.
|
WO2008124122A1
(en)
*
|
2007-04-09 |
2008-10-16 |
Scidose, Llc |
Combinations of statins and anti-obesity agent and glitazones
|
JP2010524953A
(ja)
|
2007-04-17 |
2010-07-22 |
ブリストル−マイヤーズ スクイブ カンパニー |
縮合ヘテロ環11−β−ヒドロキシステロイドデヒドロゲナーゼI型阻害剤
|
ES2434215T3
(es)
|
2007-04-18 |
2013-12-16 |
Tethys Bioscience, Inc. |
Biomarcadores relacionados con la diabetes y métodos de uso de los mismos
|
PE20090696A1
(es)
*
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
US20100086615A1
(en)
|
2007-04-27 |
2010-04-08 |
Kyushu University, National University Corporation |
Agent for treatment of pulmonary disease
|
US20080287529A1
(en)
*
|
2007-05-18 |
2008-11-20 |
Bristol-Myers Squibb Company |
Crystal structures of sglt2 inhibitors and processes for preparing same
|
EP2152700B1
(en)
|
2007-05-21 |
2013-12-11 |
Novartis AG |
Csf-1r inhibitors, compositions, and methods of use
|
EP2166843A4
(en)
|
2007-06-01 |
2010-08-11 |
Univ Princeton |
TREATMENT OF VIRUS INFECTIONS BY MODULATION OF HOST CELL METABOLISMS
|
DE102007028406A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
DE102007028407A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
DE102007028319A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
DE102007028320A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
EP2546232A1
(en)
|
2007-06-20 |
2013-01-16 |
Merck Sharp & Dohme Corp. |
Diphenyl Substituted Alkanes
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
US20090011994A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
JP2010534722A
(ja)
*
|
2007-07-27 |
2010-11-11 |
ブリストル−マイヤーズ スクイブ カンパニー |
新規グルコキナーゼ活性化薬およびその使用方法
|
US20090076148A1
(en)
*
|
2007-09-14 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched pravastatin
|
WO2009038974A1
(en)
*
|
2007-09-20 |
2009-03-26 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
ES2448839T3
(es)
|
2007-11-01 |
2014-03-17 |
Bristol-Myers Squibb Company |
Compuestos no esteroideos útiles como moderadores de la actividad del receptor de glucocorticoides AP-1 y/o NF-kappa b y uso de los mismos
|
US20090163452A1
(en)
*
|
2007-12-20 |
2009-06-25 |
Schwartz Janice B |
Compositions and methods for lowering serum cholesterol
|
CN104188971B
(zh)
|
2007-12-21 |
2017-05-03 |
配体药物公司 |
选择性雄激素受体调节剂(sarm)及其应用
|
US20090226515A1
(en)
*
|
2008-03-04 |
2009-09-10 |
Pharma Pass Ii Llc |
Statin compositions
|
US20090226516A1
(en)
*
|
2008-03-04 |
2009-09-10 |
Pharma Pass Ii Llc |
Sartan compositions
|
EP2288378A4
(en)
*
|
2008-04-16 |
2011-12-14 |
Univ Utah Res Found |
PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATION
|
PE20091928A1
(es)
*
|
2008-05-29 |
2009-12-31 |
Bristol Myers Squibb Co |
Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
|
ES2330184B1
(es)
|
2008-06-03 |
2010-07-05 |
Neuron Biopharma, S.A. |
Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
|
EP2138178A1
(en)
|
2008-06-28 |
2009-12-30 |
Bayer Schering Pharma Aktiengesellschaft |
Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
|
EP2161024A1
(de)
|
2008-09-05 |
2010-03-10 |
Universitätsklinikum Hamburg-Eppendorf |
Kombinationspräparat zur Behandlung von Krebs
|
WO2010041619A1
(ja)
|
2008-10-06 |
2010-04-15 |
メルシャン株式会社 |
シュードノカルディア・オートトロフィカ(Pseudonocardia autotrophica)発現ベクター
|
US20120046364A1
(en)
|
2009-02-10 |
2012-02-23 |
Metabasis Therapeutics, Inc. |
Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
|
US20100256153A1
(en)
|
2009-03-27 |
2010-10-07 |
Bristol-Myers Squibb Company |
Methods for preventing or reducing risk of mortality
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
TW201039815A
(en)
|
2009-04-13 |
2010-11-16 |
Resolvyx Pharmaceuticals Inc |
Compositions and methods for the treatment of inflammation
|
US8470805B2
(en)
*
|
2009-04-30 |
2013-06-25 |
Kaohsiung Medical University |
Processes for preparing piperazinium salts of KMUP and use thereof
|
MX2011012559A
(es)
|
2009-05-28 |
2012-06-08 |
Exelixis Patent Co Llc |
Moduladores de lxr.
|
WO2011014520A2
(en)
|
2009-07-29 |
2011-02-03 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
EP2486033A1
(en)
|
2009-10-09 |
2012-08-15 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
MX2012004377A
(es)
|
2009-10-14 |
2012-06-01 |
Merck Sharp & Dohme |
Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
|
AU2010319438B2
(en)
|
2009-11-13 |
2015-05-21 |
Astrazeneca Uk Limited |
Reduced mass metformin formulations
|
US8871264B2
(en)
|
2009-11-13 |
2014-10-28 |
Astrazeneca Ab |
Immediate release tablet formulations
|
US8535715B2
(en)
|
2009-11-13 |
2013-09-17 |
Bristol-Myers Squibb Company |
Bilayer tablet formulations
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
EP2512514B1
(en)
|
2009-12-14 |
2014-11-05 |
Kyoto University |
Screening method for identifying compounds for treating amyotrophic lateral sclerosis
|
CN103037829A
(zh)
|
2010-02-01 |
2013-04-10 |
儿童医院 |
用于治疗和预防再狭窄的远程缺血调节
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
SG184353A1
(en)
|
2010-03-31 |
2012-11-29 |
Hospital For Sick Children |
Use of remote ischemic conditioning to improve outcome after myocardial infarction
|
SG10201908576VA
(en)
|
2010-04-08 |
2019-10-30 |
Hospital For Sick Children |
Use of remote ischemic conditioning for traumatic injury
|
CN102971313A
(zh)
|
2010-04-14 |
2013-03-13 |
百时美施贵宝公司 |
新颖的葡糖激酶激活剂及其使用方法
|
US8372877B2
(en)
|
2010-04-16 |
2013-02-12 |
Cumberland Pharmaceuticals |
Stabilized statin formulations
|
EP2571860A1
(en)
|
2010-05-21 |
2013-03-27 |
Pfizer Inc |
2-phenyl benzoylamides
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
JP6042330B2
(ja)
|
2010-07-09 |
2016-12-14 |
ビーエイチヴィ ファーマ、インコーポレイテッド |
レモグリフロジンを含めた半減期が短い医薬品のための組合せ即時/遅延放出送達システム
|
US8697739B2
(en)
|
2010-07-29 |
2014-04-15 |
Novartis Ag |
Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
|
US8518907B2
(en)
|
2010-08-02 |
2013-08-27 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
EP3587574B1
(en)
|
2010-08-17 |
2022-03-16 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
WO2012036997A1
(en)
|
2010-09-16 |
2012-03-22 |
Schering Corporation |
Fused pyrazole derivatives as novel erk inhibitors
|
KR20130137623A
(ko)
|
2010-10-06 |
2013-12-17 |
고쿠리츠다이가쿠호우진 도쿄다이가쿠 |
림프 부종 예방 치료제
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
TWI462739B
(zh)
|
2010-11-02 |
2014-12-01 |
Univ Kaohsiung Medical |
Sildenafil-同族物四級銨哌嗪鹽類之製備及醫療用途
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
WO2012085191A1
(en)
|
2010-12-23 |
2012-06-28 |
Dsm Sinochem Pharmaceuticals Netherlands B.V. |
Crystalline form of pravastatine and process for the preparation thereof
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
AU2012208837B2
(en)
|
2011-01-20 |
2016-07-28 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
CN107056671A
(zh)
|
2011-01-31 |
2017-08-18 |
卡迪拉保健有限公司 |
脂肪代谢障碍的治疗
|
EP2675440B1
(en)
|
2011-02-14 |
2020-03-25 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
JP2014513923A
(ja)
|
2011-03-04 |
2014-06-19 |
ファイザー・インク |
Edn3様ペプチドおよびその使用
|
AR088728A1
(es)
|
2011-03-25 |
2014-07-02 |
Bristol Myers Squibb Co |
Moduladores de lxr como prodroga de imidazol
|
US9487506B2
(en)
|
2011-04-13 |
2016-11-08 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
AU2012245971A1
(en)
|
2011-04-21 |
2013-10-17 |
Piramal Enterprises Limited |
A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
EP2765859B1
(en)
|
2011-10-13 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
KR101466617B1
(ko)
|
2011-11-17 |
2014-11-28 |
한미약품 주식회사 |
오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
|
US20150010630A1
(en)
|
2011-12-29 |
2015-01-08 |
Trustees Of Tufts College |
Functionalization of biomaterials to control regeneration and inflammation responses
|
WO2013113067A1
(en)
|
2012-02-02 |
2013-08-08 |
The University Of Sydney |
Improvements in tear film stability
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
US9783614B2
(en)
|
2012-05-10 |
2017-10-10 |
Bayer Pharma Aktiengesellschaft |
Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof
|
SG11201407402TA
(en)
|
2012-05-11 |
2014-12-30 |
Reset Therapeutics Inc |
Carbazole-containing sulfonamides as cryptochrome modulators
|
WO2014022195A1
(en)
|
2012-08-01 |
2014-02-06 |
Tavakoli Zahra |
Free flowing, frozen compositions comprising a therapeutic agent
|
US8729092B2
(en)
|
2012-09-24 |
2014-05-20 |
Terence J. Scallen |
Rosuvastatin enantiomer compounds
|
WO2014052619A1
(en)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Piperidine derivatives and compositions as modulators of gpr119 activity
|
MX2015004041A
(es)
|
2012-09-28 |
2015-07-06 |
Merck Sharp & Dohme |
Compuestos novedosos que son inhibidores de erk.
|
US9200025B2
(en)
|
2012-11-20 |
2015-12-01 |
Lexicon Pharmaceuticals, Inc. |
Inhibitors of sodium glucose cotransporter 1
|
CA2892361A1
(en)
|
2012-11-28 |
2014-06-05 |
Merck Sharp & Dohme Corp. |
Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels
|
ES2707305T3
(es)
|
2012-12-20 |
2019-04-03 |
Merck Sharp & Dohme |
Imidazopiridinas sustituidas como inhibidores de HDM2
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
JP6442475B2
(ja)
|
2013-03-15 |
2018-12-19 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Lxr調節因子
|
KR101951075B1
(ko)
|
2013-03-21 |
2019-02-21 |
유프락시아 파마수티컬스 유에스에이 엘엘씨 |
주입가능한 서방성 방출 조성물 및 관절 내 염증 및 이와 관련된 통증을 치료하기 위해 이를 사용하는 방법
|
AU2014255381A1
(en)
|
2013-04-17 |
2015-10-08 |
Pfizer Inc. |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
EA201592020A1
(ru)
|
2013-04-22 |
2016-05-31 |
Кадила Хелзкэр Лимитед |
Новая композиция для неалкогольной жировой болезни печени (нажбп)
|
EP3004053B1
(en)
|
2013-05-30 |
2021-03-24 |
Cadila Healthcare Limited |
A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
|
TW201636015A
(zh)
|
2013-07-05 |
2016-10-16 |
卡地拉保健有限公司 |
協同性組成物
|
IN2013MU02470A
(da)
|
2013-07-25 |
2015-06-26 |
Cadila Healthcare Ltd |
|
WO2015027021A1
(en)
|
2013-08-22 |
2015-02-26 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
IN2013MU02905A
(da)
|
2013-09-06 |
2015-07-03 |
Cadila Healthcare Ltd |
|
WO2015051479A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
AU2014332250B2
(en)
|
2013-10-08 |
2018-07-19 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
JP6536871B2
(ja)
|
2013-12-02 |
2019-07-03 |
国立大学法人京都大学 |
Fgfr3病の予防および治療剤ならびにそのスクリーニング方法
|
WO2015108988A2
(en)
|
2014-01-17 |
2015-07-23 |
Ligand Pharmaceuticals, Inc. |
Methods and compositions for modulating hormone levels
|
WO2015120580A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
TWI690521B
(zh)
|
2014-04-07 |
2020-04-11 |
美商同步製藥公司 |
作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
|
SG11201609050UA
(en)
|
2014-05-30 |
2016-12-29 |
Pfizer |
Carbonitrile derivatives as selective androgen receptor modulators
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
EP3194024B1
(en)
|
2014-09-15 |
2020-08-05 |
The Board of Trustees of the Leland Stanford Junior University |
Targeting aneurysm disease by modulating phagocytosis pathways
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
ES2838925T3
(es)
|
2015-02-27 |
2021-07-02 |
Univ Leland Stanford Junior |
Terapia de combinación para el tratamiento de la ateroesclerosis
|
EP3288584A2
(en)
|
2015-04-30 |
2018-03-07 |
President and Fellows of Harvard College |
Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
|
WO2017064635A2
(en)
|
2015-10-14 |
2017-04-20 |
Cadila Healthcare Limited |
Pyrrole compound, compositions and process for preparation thereof
|
EP3206672B1
(en)
|
2015-10-27 |
2018-03-14 |
Eupraxia Pharmaceuticals Inc. |
Sustained release formulations of local anesthetics
|
US20180243263A1
(en)
|
2016-12-09 |
2018-08-30 |
Cadila Healthcare Ltd. |
Treatment for primary biliary cholangitis
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2019216313A1
(ja)
|
2018-05-08 |
2019-11-14 |
国立大学法人岡山大学 |
心血管疾患に有用な医薬
|
WO2020017575A1
(ja)
|
2018-07-19 |
2020-01-23 |
国立大学法人京都大学 |
多能性幹細胞由来の板状軟骨およびその製造方法
|
EA202190226A1
(ru)
|
2018-07-19 |
2021-06-16 |
Астразенека Аб |
СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020068661A1
(en)
|
2018-09-26 |
2020-04-02 |
Lexicon Pharmaceuticals, Inc. |
Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
|
US20220056413A1
(en)
|
2018-12-21 |
2022-02-24 |
Kyoto University |
Lubricin-localized cartilage-like tissue, method for producing same and composition comprising same for treating articular cartilage damage
|
EP3911648A4
(en)
|
2019-01-18 |
2022-10-26 |
Astrazeneca AB |
PCSK9 INHIBITORS AND METHODS OF USE THEREOF
|
CN113316469A
(zh)
|
2019-03-13 |
2021-08-27 |
国立大学法人浜松医科大学 |
主动脉瘤的治疗用医药组合物
|
CR20210669A
(es)
|
2019-05-27 |
2022-05-05 |
Immatics Us Inc |
Vectores víricos y uso de los mismos en terapias celulares adoptivas
|
MX2022007535A
(es)
|
2019-12-17 |
2022-09-23 |
Merck Sharp & Dohme Llc |
Inhibidores de prmt5.
|
EP4108260A4
(en)
|
2020-02-21 |
2024-03-06 |
Jsr Corp |
COMPOSITION FOR RELIEF PULMONARY HYPERTENSION, METHOD FOR PREDICTING THE PROGNOSIS OF PULMONARY HYPERTENSION, METHOD FOR AIDING IN DETERMINING THE SEVERITY OF PULMONARY HYPERTENSION, AND METHOD FOR AIDING IN THE DIAGNOSIS OF PULMONARY HYPERTENSION
|
DE102020111571A1
(de)
|
2020-03-11 |
2021-09-16 |
Immatics US, Inc. |
Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
|
WO2022022865A1
(en)
|
2020-07-27 |
2022-02-03 |
Astrazeneca Ab |
Methods of treating chronic kidney disease with dapagliflozin
|
TW202227616A
(zh)
|
2020-08-21 |
2022-07-16 |
美商英麥提克斯股份有限公司 |
分離cd8+選擇t細胞的方法
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|
WO2023144722A1
(en)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
|